Enovis Corporation · NYSE:ENOV
Enovis — Q2 2026 Earnings Presentation
24 slides from Enovis's earnings presentation, Aug 6, 2026
Slide 1: Second Quarter 2026 Results
Second Quarter 2026 Results August 6, 2026
Slide 2: Forward-looking Statements Non-GAAP Financial Information
Forward-looking Statements Non-GAAP Financial Information This presentation includes forward-looking statements, including forward-looking statements within Enovis has provided in this presentation financial information that has not been prepared in accordance with the meaning of the U.S. Private Se
Slide 3: Q2 2026 Highlights
Q2 2026 Highlights • +5% organic growth, ~90 basis point tailwind from selling days • +6% organic growth in Recon, +5% days adjusted • +3% organic growth in P&R, +3% days adjusted • Initial Arvis feedback very encouraging, still early in Shoulder rollout • Generated $31M in Free Cash Flow in Q2 Cont
Slide 4: Q2 Reconstructive Segment Sales Performance
Q2 Reconstructive Segment Sales Performance Reconstructive Q2 Sales Growth: +8% Y/Y, +6% organic • WW organic growth of +6% • +7% organic growth in Extremities • +5% organic growth in Hip/Knee • U.S. organic growth of +6% Q2 ‘26 • +5% organic growth in Extremities Extremities Sales Hip & Knee • +8%
Slide 5: Q2 Prevention & Recovery Segment Sales Performance
Q2 Prevention & Recovery Segment Sales Performance P&R Q2 Sales Growth: -1% Y/Y, +3% organic • WW organic growth of 3% • Global Bracing 4% • Expanded Adjusted Gross Margin by +210bps inclusive of inflationary impacts • Driven by product mix and divestiture of Dr. Comfort Recovery Sciences • Includes
Slide 6: P&L Performance
P&L Performance Millions Q2 2025 Q2 2026 Millions H1 2025 H1 2026 Net Sales $565 $583 Net Sales $1,123 $1,172 Adj. Gross Profit $336 $360 Adj. Gross Profit $668 $726 Margin(1) 59.4% 61.7% Margin(1) 59.5% 61.9% Adj. EBITDA $91 $104 Adj. EBITDA $178 $208 Margin(1) 16.2% 17.9% Margin(1) 15.9% 17.7% Adj
Slide 7: Capital Allocation
Capital Allocation Key Metrics as of Q2 2026 Strategic Priorities Cash Flow • Increase free cash flow • Free cash flow improved $27M vs Q2 25 • $31M of Free Cash Flow • Support organic growth through CAPEX • On track for +25% free cash flow conversion • $1.3B in total debt and R&D investments in 202
Slide 8: Full Year 2026 Outlook
Full Year 2026 Outlook February May August Comments & Assumptions • Global markets grow in line with historical Reported Revenue $2.31-$2.37B $2.31-$2.37B $2.31-$2.37B averages • ~4.0-6.0% organic growth aEBITDA $425-$435M $425-$435M $425-$435M • 0.5-1.5% FX tailwind at current rates • HSD Recon gro
Slide 9: Phasing Considerations
Phasing Considerations 2026 growth vs PY – Organic Days Adjusted Comments 8% M/HSD 5% ~5-6% • Historical 3Q seasonality, softer Western Recon Europe volumes, and Middle East conflict Q1 Q2 Q3e Q4e • Cross-selling and new launches weighted to 4Q MSD 3% 3% ~3% P&R • P&R accelerating into H2 on new pro
Slide 10: Summary
Summary • Solid execution against an increasingly dynamic operating and geopolitical environment • Above market growth in both Recon and P&R fueled by new products and commercial discipline • Multi-year roadmap of new product launches supports continued growth trajectory • 2026 guidance reaffirmed ©
Slide 11: Appendix
Appendix enovis. Creating Better Together” ma
Slide 12: QTD Revenue Growth Bridge
QTD Revenue Growth Bridge Three Months Ended July 3, 2026 US US INT'L Enovis Recon P&R Extremeties HIP/KNEE RECON Reported Growth 3% 8% -1% 5% 8% 8% FX Benefit -1% -1% -1% 0% 0% -2% Acq/Divest 3% 0% 5% 0% 0% 0% Organic Growth 5% 6% 3% 5% 8% 6% Days Impact -1% -1% -1% -1% -1% -1% Organic, Days Adjust
Slide 13: Revenue Growth Bridge YTD
Revenue Growth Bridge YTD Six Months Ended July 3, 2026 US US INT'L Enovis Recon P&R Extremeties HIP/KNEE RECON Reported Growth 4% 9% -1% 8% 7% 11% FX Benefit -3% -3% -2% 0% 0% -6% Acq/Divest 2% 0% 5% 0% 0% 0% Organic Growth 4% 6% 2% 8% 7% 5% Days Impact 1% 1% 1% 1% 1% 1% Organic, Days Adjusted 5% 7
Slide 14: Reconciliation of Impact of Change in Non-GAAP Measures
Reconciliation of Impact of Change in Non-GAAP Measures © 2026 Enovis Corporation 14
Slide 15: QTD Sales Bridge
QTD Sales Bridge Net Sales Prevention and Recovery Reconstructive Total Enovis $ Change % $ Change % $ Change % For the three months ended July 4, 2025 $ 290.6 $ 274.0 $ 564.5 Components of Change: Existing Businesses(1) 10.1 3.5 % 17.2 6.3 % 27.3 4.8 % Acquisitions(2) — —% — —% — —% Divestitures(3)
Slide 16: YTD Sales Bridge
YTD Sales Bridge Net Sales Prevention and Recovery Reconstructive Total Enovis $ Change % $ Change % $ Change % For the six months ended July 4, 2025 $ 563.2 $ 560.2 $ 1,123.4 Components of Change: Existing Businesses(1) 12.6 2.2 % 33.0 5.9 % 45.6 4.1 % Acquisitions(2) 1.3 0.2 % — —% 1.3 0.1 % Dives
Slide 17: QTD Adjusted EPS Reconciliation
QTD Adjusted EPS Reconciliation Three Months Ended July 3, 2026 July 4, 2025 Six Months Ended July 3, 2026 July 4, 2025 Adjusted Net Income and Adjusted Net Income Per Share Net Loss (GAAP) $ (1.0) $ (36.5) $ (9.5) $ (92.3) Net loss margin (GAAP) (0.2)% (6.5)% (0.8)% (8.2)% Net income attributable t
Slide 18: QTD Adjusted EPS Reconciliation
(1) Net income (loss) from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net income (loss) from continuing operations less net income attributable to noncontrolling interest from continuing operations - net of taxes. QTD (2) Restructuring cha
Slide 19: QTD Adjusted EBITDA Reconciliation
QTD Adjusted EBITDA Reconciliation Three Months Ended Six Months Ended July 3, 2026 July 4, 2025 July 3, 2026 July 4, 2025 (Dollars in millions) Net loss (GAAP) $ (1.0) $ (36.5) $ (9.5) $ (92.3) Net loss margin (GAAP) (0.2)% (6.5)% (0.8)% (8.2)% Loss from discontinued operations, net of taxes — 0.1
Slide 20: Adjusted EBITDA Reconciliation
Adjusted (1) Restructuring charges reflect costs associated with the Company’s restructuring programs to reduce the structural costs of the Company. For further information, see Note 10, “Accrued Liabilities - Accrued Restructuring Liability” included in our Form 10-Q. Includes expenses of $0.2 mill
Slide 21: QTD Adjusted Gross Margin Reconciliation (Unaudited)
QTD Adjusted Gross Margin Reconciliation (Unaudited) Three Months Ended Six Months Ended July 03, 2026 July 04, 2025 July 03, 2026 July 04, 2025 Net sales $ 582.8 $ 564.5 $ 1,171.9 $ 1,123.4 Gross profit $ 359.2 $ 334.7 $ 724.7 $ 666.9 Gross profit margin (GAAP) 61.6 % 59.3 % 61.8 % 59.4 % Gross pro
Slide 22: Q2'26 GAAP to Adjusted Non-GAAP Financial Measures
Q2’26 GAAP to Adjusted Non-GAAP Financial Measures Dollars in millions (Unaudited) Enovis Acquisition- Restructuring & Related Non- Other Income Tax Continuing Cash Other Adjustmentsc Adjustmentd Adjusted Operations Adjustmentsb Adjustmentsa Net sales $ 582.8 $ — $ — $ — $ — $ 582.8 Cost of goods so
Slide 23: Q2'25 GAAP to Adjusted Non-GAAP Financial Measures
Q2’25 GAAP to Adjusted Non-GAAP Financial Measures Dollars in millions (Unaudited) Enovis Acquisition- Restructuring & Related Non- Other Income Tax Adjusted Continuing Cash Other Adjustmentsc Adjustmentd Operations Adjustmentsb Adjustmentsa Net sales $ 564.5 $ — $ — $ — $ — $ 564.5 Cost of goods so
Slide 24: enovis. Creating Better Together
enovis. Creating Better Together”